|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||111.01 - 114.67|
|52 Week Range||93.13 - 130.40|
|Beta (5Y Monthly)||0.15|
|PE Ratio (TTM)||37.09|
|Forward Dividend & Yield||2.79 (2.17%)|
|Ex-Dividend Date||Aug 12, 2021|
|1y Target Est||N/A|
Investing in stocks that are falling can be tough to do; nobody wants to look at their portfolio and see red. Shares of COVID-19 vaccine-maker AstraZeneca are down 5% over the past three months, while the S&P 500 has soared by more than 5%. Up until now, AstraZeneca hasn't been trying to make a profit from its COVID-19 vaccine.
AstraZeneca said on Friday it was examining the impact of a new coronavirus variant that is spreading rapidly in South Africa on its vaccine and its antibody cocktail, adding it was hopeful its combination drug would retain efficacy. The World Health Organization (WHO) on Friday designated a new COVID-19 variant B.1.1.529, detected in South Africa with a large number of mutations, as being "of concern". AstraZeneca has distributed 2 billion doses of its vaccine worldwide, although rollout of the shot was paused in South Africa in February after it was shown to offer minimal protection against mild to moderate illness caused by the Beta variant, which was dominant in the country at the time.
Stifel Chief Equity Strategist Barry Bannister joins Yahoo Finance Live to discuss the investor implications of a newly discovered COVID-19 variant as we enter the second winter of the pandemic.